The Utilization and Safety of Umeclidinium and Umeclidinium/Vilanterol in UK Primary Care: A Retrospective Cohort Study

References

• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease 2021 report; 2021. Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. Accessed March 05, 2021.
   Google Scholar
• Global Initiative for Asthma. Asthma Management and Prevention for Adults and Children Older than 5 Years: A Pocket Guide for Health Professionals; 2020. Available from: https://ginasthma.org/wp-content/uploads/2020/04/Main-pocket-guide_2020_04_03-final-wms.pdf. Accessed March 05, 2021.
   Google Scholar
• National Institute for Health and Care Excellence. Asthma: tiotropium (Spiriva Respimat). 2015. Available from: https://www.nice.org.uk/advice/esnm55/chapter/Key-points-from-the-evidence. Accessed March 05, 2021.
   Google Scholar
• European Medicines Agency. Anoro Ellipta (umeclidinium bromide/vilanterol) An overview of Anoro Ellipta and why it is authorised in the EU; 2018. Available from: https://www.ema.europa.eu/en/documents/overview/anoro-ellipta-epar-medicine-overview_en.pdf. Accessed 26 June, 2020.
   Google Scholar
• European Medicines Agency. Incruse Ellipta (umeclidinium bromide) An overview of Incruse Ellipta and why it is authorised in the EU; 2018. Available from: https://www.ema.europa.eu/en/documents/overview/incruse-ellipta-epar-medicine-overview_en.pdf. Accessed 18 June, 2020.
   Google Scholar
• Ray R, Tombs L, Naya I, Compton C, Lipson DA, Boucot I. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: a pooled post hoc analysis of seven clinical trials. Pulm Pharmacol Ther. 2019;57:101802. doi:10.1016/j.pupt.2019.101802
   PubMed Web of Science ®Google Scholar
• Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014;108(12):1752–1760. doi:10.1016/j.rmed.2014.10.002
   PubMed Web of Science ®Google Scholar
• Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107(10):1538–1546. doi:10.1016/j.rmed.2013.06.001
   PubMed Web of Science ®Google Scholar
• Zheng J, Zhong N, Newlands A, Church A, Goh AH. Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study. Int J Chron Obstruct Pulmon Dis. 2015;10:1753–1767. doi:10.2147/copd.s81053
   PubMed Web of Science ®Google Scholar
• Albertson TE, Bowman WS, Harper RW, Godbout RM, Murin S. Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:1251–1265. doi:10.2147/COPD.S191845
   PubMed Web of Science ®Google Scholar
• Pleasants RA, Wang T, Gao J, Tang H, Donohue JF. Inhaled Umeclidinium in COPD patients: a review and meta-analysis. Drugs. 2016;76(3):343–361. doi:10.1007/s40265-015-0532-5
   PubMed Web of Science ®Google Scholar
• Feldman G, Maltais F, Khindri S, et al. A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 µg compared with tiotropium 18 µg in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:719–730. doi:10.2147/COPD.S102494
   PubMed Web of Science ®Google Scholar
• Trivedi R, Richard N, Mehta R, Church A. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J. 2014;43(1):72–81. doi:10.1183/09031936.00033213
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Müllerová H, Hurst JR, et al. Validation of the Recording of Acute Exacerbations of COPD in UK Primary care electronic healthcare records. PLoS One. 2016;11(3):e0151357. doi:10.1371/journal.pone.0151357
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Müllerová H, Thomas SL, et al. Recording of hospitalizations for acute exacerbations of COPD in UK electronic health care records. Clin Epidemiol. 2016;8:771–782. doi:10.2147/CLEP.S117867
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Long-Acting Bronchodilator Initiation in COPD and the risk of adverse cardiopulmonary events: a population-based comparative safety study. Chest. 2017;151(1):60–67. doi:10.1016/j.chest.2016.08.001
   PubMed Web of Science ®Google Scholar
• Jara M, Wentworth C, Lanes S. A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD. BMJ Open. 2012;2(3):e000841. doi:10.1136/bmjopen-2012-000841
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative Effectiveness and Safety of LABA-LAMA vs LABA-ICS Treatment of COPD in Real-World Clinical Practice. Chest. 2019;155(6):1158–1165. doi:10.1016/j.chest.2019.03.005
   PubMed Web of Science ®Google Scholar
• Pate A, Barrowman M, Webb D, et al. Study investigating the generalisability of a COPD trial based in primary care (Salford Lung Study) and the presence of a Hawthorne effect. BMJ Open Respir Res. 2018;5(1):e000339. doi:10.1136/bmjresp-2018-000339
   PubMed Web of Science ®Google Scholar
• Rebordosa C, Aguado J, Plana E, et al. Use of aclidinium did not increase the risk of death in a noninterventional cohort study in the Clinical Practice Research Datalink (CPRD), United Kingdom. Respir Med. 2019;152:37–43. doi:10.1016/j.rmed.2019.04.018
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008;63(9):831–838. doi:10.1136/thx.2007.086041
   PubMed Web of Science ®Google Scholar
• Mäkelä MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013;107(10):1481–1490. doi:10.1016/j.rmed.2013.04.005
   PubMed Web of Science ®Google Scholar
• Moretz C, Bengtson LG, Sharpsten L, et al. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol. Int J Chron Obstruct Pulmon Dis. 2019;14:2047–2060. doi:10.2147/COPD.S213520
   PubMed Web of Science ®Google Scholar
• Moretz C, Sharpsten L, Bengtson LG, et al. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study. Int J Chron Obstruct Pulmon Dis. 2019;14:1721–1737. doi:10.2147/COPD.S204649
   PubMed Web of Science ®Google Scholar
• Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ. Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over. J Asthma. 2006;43(1):75–80. doi:10.1080/02770900500448738
   PubMed Web of Science ®Google Scholar